Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$13.00 +2.9%	$11.42	$3.98 ▼ $13.40	$1.92B	1.92	2.17 million shs	1.95 million shs
ATIP ATI Physical Therapy	$0.68	$0.80	$0.01 ▼ $6.59	$2.98M	-0.15	9,934 shs	10 shs
CELC Celcuity	$52.42 +4.0%	$26.23	$7.57 ▼ $53.85	$2.14B	0.68	3.03 million shs	956,376 shs
SNDA Shanda Interactive Entertainment	$26.66 +16.9%	$0.00	$19.34 ▼ $32.90	$479.80M	1.83	52,862 shs	32,857 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+2.93%	-0.31%	+19.60%	+45.58%	+182.00%
ATIP ATI Physical Therapy	0.00%	0.00%	+87.50%	-25.00%	-88.58%
CELC Celcuity	+4.05%	+1.22%	+273.10%	+402.11%	+208.53%
SNDA Shanda Interactive Entertainment	+3.32%	+5.42%	+6.64%	+8.34%	-1.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.4324 of 5 stars	1.4	1.0	0.0	4.2	1.9	1.7	0.6
ATIP ATI Physical Therapy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	1.174 of 5 stars	1.5	2.0	0.0	0.0	2.9	3.3	0.0
SNDA Shanda Interactive Entertainment	0.1534 of 5 stars	1.0	1.0	0.0	0.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-4.81% Downside
ATIP ATI Physical Therapy	0.00	N/A	N/A	N/A
CELC Celcuity	3.00	Buy	$50.60	-3.47% Downside
SNDA Shanda Interactive Entertainment	2.00	Hold	$26.00	-2.46% Downside

Current Analyst Ratings Breakdown

Latest SNDA, ATIP, CELC, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $66.00
8/15/2025	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $70.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
7/28/2025	CELC Celcuity	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $60.00
7/28/2025	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $50.00
7/28/2025	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00
7/1/2025	CELC Celcuity	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/30/2025	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	11.06	N/A	N/A	$1.18 per share	11.02
ATIP ATI Physical Therapy	$741.86M	0.00	$3.55 per share	0.19	($23.96) per share	-0.03
CELC Celcuity	N/A	N/A	N/A	N/A	$1.05 per share	N/A
SNDA Shanda Interactive Entertainment	$255.32M	1.99	N/A	N/A	($14.07) per share	-1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
ATIP ATI Physical Therapy	-$69.79M	-$19.42	N/A	∞	N/A	-7.79%	N/A	-3.87%	11/3/2025 (Estimated)
CELC Celcuity	-$111.78M	-$3.45	N/A	N/A	N/A	N/A	-150.07%	-64.67%	N/A
SNDA Shanda Interactive Entertainment	-$21.11M	-$1.85	N/A	N/A	N/A	-4.02%	N/A	-6.11%	N/A

Latest SNDA, ATIP, CELC, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CELC Celcuity	-$0.90	-$1.04	-$0.14	-$1.04	N/A	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ATIP ATI Physical Therapy	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
SNDA Shanda Interactive Entertainment	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
ATIP ATI Physical Therapy	N/A	1.12	1.12
CELC Celcuity	2.24	4.58	6.61
SNDA Shanda Interactive Entertainment	6.97	2.34	2.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ATIP ATI Physical Therapy	72.60%
CELC Celcuity	63.33%
SNDA Shanda Interactive Entertainment	87.55%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ATIP ATI Physical Therapy	3.30%
CELC Celcuity	15.77%
SNDA Shanda Interactive Entertainment	5.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
ATIP ATI Physical Therapy	5,600	4.41 million	4.27 million	No Data
CELC Celcuity	40	42.43 million	35.74 million	Optionable
SNDA Shanda Interactive Entertainment	3,955	19.07 million	18.12 million	Not Optionable

SNDA, ATIP, CELC, and ADPT Headlines

Recent News About These Companies

Sonida Senior Living (SNDA) Reports Q2 Loss, Beats Revenue Estimates

August 11, 2025 | zacks.com

Sonida Senior Living, Inc. (SNDA) Q2 2025 Earnings Conference Call Transcript

August 11, 2025 | seekingalpha.com

Sonida Senior Living Celebrates Growth and Community in Greater Atlanta Region

July 30, 2025 | businesswire.com

Vista Building at The Wellington at North Bend Crossing Secures Ohio Licensure, Opening Doors for New Assisted Living and Memory Care Residents

July 30, 2025 | businesswire.com

Sonida Senior Living, Inc. (SNDA) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Sonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

Sonida Senior Living Announces First Quarter 2025 Results

May 12, 2025 | businesswire.com

Sonida Announces Participation in Upcoming Conferences

May 8, 2025 | businesswire.com

The Wellington at North Bend Crossing Expands Assisted Living and Memory Care Services, Coming Summer 2025

May 2, 2025 | businesswire.com

Sonida Senior Living, Inc. (SNDA) Q4 2024 Earnings Call Transcript

March 17, 2025 | seekingalpha.com

Sonida Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call

March 3, 2025 | businesswire.com

Sonida to Participate in Citi's 30th Annual Global Property CEO Conference

February 17, 2025 | businesswire.com

Sonida Senior Living Advances Clinical Excellence with August Health

February 6, 2025 | businesswire.com

Sonida Announces Latest Asset Acquisition and Closing of Fannie Mae Maturity Modifications

January 6, 2025 | businesswire.com

Sonida Senior Living, Inc. (SNDA) Q3 2024 Earnings Call Transcript

November 15, 2024 | seekingalpha.com

Sonida Senior Living Announces Third Quarter 2024 Results

November 13, 2024 | businesswire.com

Sonida Continues Executing on its Accretive Growth and Capital Allocation Strategy with $48 Million of Investments

November 5, 2024 | businesswire.com

Sunda Energy Share Chat (SNDA)

November 4, 2024 | lse.co.uk

Interactive Harry Potter art experience to open on Sentosa on Nov 22

November 1, 2024 | straitstimes.comS

Sonida Announces Third Quarter 2024 Earnings Release Date and Conference Call

October 29, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDA, ATIP, CELC, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$13.00 +0.37 (+2.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.86 -0.14 (-1.08%)

As of 08/22/2025 07:35 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ATI Physical Therapy NYSE:ATIP

$0.68 0.00 (0.00%)

As of 07/31/2025

ATI Physical Therapy, Inc. operates as an outpatient physical therapy provider that specializes in outpatient rehabilitation and adjacent healthcare services in the United States. It offers a range of services to its patients, including physical therapy to treat spine, shoulder, knee, and neck injuries or pain; work injury rehabilitation services, work conditioning and work hardening; and hand therapy, aquatic therapy, functional capacity evaluation, sports medicine, and wellness programs. It also provides ATI worksite solutions comprising injury prevention programs, work-related injury assessment services, wellness offerings, and consultations for employers; proprietary electronic medical records (EMR) integration, caseload management, and continuing education in therapy treatments; and sports medicine, including on-site sports physical therapy, clinical evaluation and diagnosis, immediate and emergency care, nutrition programs, and concussion management services. The company offers outpatient physical therapy services under the ATI brand name. ATI Physical Therapy, Inc. was founded in 1996 and is based in Bolingbrook, Illinois.

Celcuity NASDAQ:CELC

$52.42 +2.04 (+4.05%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$51.58 -0.84 (-1.61%)

As of 08/22/2025 07:37 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Shanda Interactive Entertainment NASDAQ:SNDA

Shanda Interactive Entertainment Limited (Shanda Interactive) is an interactive entertainment media company. The Company offers a range of entertainment content portfolio, including among other things, massively multiplayer online role-playing game (MMORPG), advanced casual games and browser-based games without user-end software through Shanda Games, online (Internet and wireless value added services (WVAS)) and offline literature publication through Cloudary Corporation, a social network game community, including among others, online chess and board games, e-sports game platform and table game platform through Shanda Casual Community, WVAS and music through Hurray and online video through Ku6. In February 2012, Shanda Interactive merged with Premium Lead Company Limited and New Era Investment Holding Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time